CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.

CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.

This invention provides a method of treating a subject afflicted with a cancer comprising periodically administering to the subject an amount of a FABP5 inhibitor and an amount of an anticancer therapy, wherein the amounts when taken together are effective to treat the subject. This invention also provides FABP5 inhibitors for use as an add-on therapy or in combination with an anticancer therapy or in treating a subject afflicted with a cancer. This invention also provides the use of a FABP5 inhibitor in the manufacturing of a medicament for use in combination or as an add on with an anticancer therapy in treating a subject afflicted with cancer, wherein the FABP5 inhibitor and the anticancer therapy are administered simultaneously, contemporaneously or concomitantly. This invention also provides a pharmaceutical composition comprising an amount of a FABP5 inhibitor and an amount of an anticancer therapy for use in treating a subject afflicted with a cancer, wherein the FABP5 inhibitor and an anticancer therapy are administered sequentially or simultaneously.

This invention provides a method of treating a subject afflicted with a cancer comprising periodically administering to the subject an amount of a FABP5 inhibitor and an amount of an anticancer therapy, wherein the amounts when taken together are effective to treat the subject. This invention also provides FABP5 inhibitors for use as an add-on therapy or in combination with an anticancer therapy or in treating a subject afflicted with a cancer. This invention also provides the use of a FABP5 inhibitor in the manufacturing of a medicament for use in combination or as an add on with an anticancer therapy in treating a subject afflicted with cancer, wherein the FABP5 inhibitor and the anticancer therapy are administered simultaneously, contemporaneously or concomitantly. This invention also provides a pharmaceutical composition comprising an amount of a FABP5 inhibitor and an amount of an anticancer therapy for use in treating a subject afflicted with a cancer, wherein the FABP5 inhibitor and an anticancer therapy are administered sequentially or simultaneously.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

Compounds of formula (I) and novel uses of compounds of formula (I), such as for flavour compositions. New preparations and new methods using compounds of formula (I).

Compounds of formula (I) and novel uses of compounds of formula (I), such as for flavour compositions. New preparations and new methods using compounds of formula (I).

The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.